Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06018740
Other study ID # 20356
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 14, 2023
Est. completion date November 13, 2023

Study information

Verified date February 2024
Source Hologram Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Symptoms of perimenopause and menopause can significantly affect overall quality of life. It is hypothesized that daily supplements can reduce the severity of these symptoms. This 12-week clinical trial will examine the effects of Hologram Sciences' Daily Balance Gummy Supplements on symptoms including hot flashes, night sweats, mood swings, anxiety, fatigue, and brain fog. Participants will take the product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12. Upon conclusion of Week 12, participants will be asked to count how many gummies remain in their jar.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date November 13, 2023
Est. primary completion date November 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: Women aged 40-65 years old Must be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, irregular or absent periods, or vaginal changes Must experience hot flashes and/or night sweats at least 5 times per day Can be either natural or surgical menopause (or perimenopause) Willing to adhere to the study protocol for the duration of the study Willing to consult with their physician prior to starting the trial if taking any of the following medications: Levothyroxine Liothyronine Calcipotriene (Dovonex) Digoxin (Lanoxin) Diltiazem (Cardizem) Verapamil (Calan, others) Thiazide diuretics Atorvastatin (Lipitor) Warfarin - Might increase the amount of time it takes for blood clotting. Minosalicylic acid (Paser) Colchicine (Colcrys, Mitigare, Gloperba) Metformin (Glumetza, Fortamet, others) Proton pump inhibitors (omeprazole (Prilosec), lansoprazole (Prevacid) or other stomach acid-reducing drugs) Phenytoin (Dilantin) Antihypertensive drugs Phenobarbital (Luminal) Amiodarone (Cordarone) Levodopa Exclusion Criteria: Not experiencing hot flashes and/or night sweats at least 5 times per day Has taken herbal supplements or multivitamins within the last 1 month Current use of conventional hormone replacement therapies, or plan to start during the study duration Current use of hormonal birth control, or plan to start during the study duration Known allergies to any product ingredients including the purified isoflavone genistein History of uterine fibroids, endometriosis, polycystic ovarian syndrome, or history of abnormal pap smear Anyone with any known severe allergies requiring the use of an epi-pen Unwilling to adhere to the study protocol Anyone living with uncontrolled or chronic health disorders, including oncological or psychiatric disorders No planned invasive medical procedures for the duration of the study Pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Daily Balance Gummy
Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.

Locations

Country Name City State
United States Citruslabs Santa Monica California

Sponsors (2)

Lead Sponsor Collaborator
Hologram Sciences Citruslabs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in score on the Menopause Rating Scale (MRS). [Baseline to Week 12] The Menopause Rating Scale (MRS) is a commonly used assessment tool in medical and research settings to evaluate the severity and impact of menopausal symptoms on women's lives. 5 point Likert scale, with the following points relating to menopausal symptoms: 0 - None (absent)
- Mild (light)
- Moderate (medium)
- Severe (heavy)
- Very severe (very heavy)
12 weeks
Primary Change in hot flashes. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of changes in hot flashes. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('Extremely often') and 5 representing the most beneficial response (i.e., "never"). 12 weeks
Primary Change in night sweats. [Baseline to 12 Weeks] Survey-based assessment (0-5 point scale) of changes in night sweats. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('severe') and 5 represents the most beneficial response (i.e., "not noticeable"). 12 weeks
Primary Change in brain fog. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of changes in brain fog. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('severe') and 5 represents the most beneficial response (i.e., "not noticeable"). 12 weeks
Primary Change in mood swings. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of changes in mood swings. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('severe') and 5 represents the most beneficial response (i.e., "not noticeable"). 12 weeks
Primary Change in sleep disturbances. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of changes in sleep disturbances. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('severe') and 5 represents the most beneficial response (i.e., "not noticeable"). 12 weeks
Primary Change in fatigue. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of changes in fatigue. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('severe') and 5 represents the most beneficial response (i.e., "not noticeable"). 12 weeks
Secondary Changes in participant-reported quality of life. [Baseline to Week 12] Survey-based assessment (0-5 point scale) of quality of life. The survey has been designed specifically for use in this study and includes study-specific questions. Data will be collected using a textual 5-point Likert scale for each question, such as "Not noticeable" to "severe." A score of 0 represents the least favorable/worse outcome ('Very Poor') and 5 represents the most beneficial response (i.e., "Excellent"). 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04553029 - A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
Completed NCT03672513 - Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause N/A
Terminated NCT03642119 - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04210583 - RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Completed NCT05617287 - An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause N/A
Recruiting NCT05180266 - Therapeutic Touch and Music in The Menopausal Period N/A
Recruiting NCT04043520 - Bioenergetic Effects of Aging and Menopause (BEAM) Phase 4
Completed NCT03663075 - Effect of Group Education and Individual Counselling on Mental Health and Quality of Life in 45-60 Year Old Women N/A
Completed NCT03363997 - Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days Phase 1
Not yet recruiting NCT04728126 - Menopausal Symptoms and Burnout: Comparison of Occupational Health Issue Among Health Professionals in UMC Hospitals
Not yet recruiting NCT04724135 - Assessment of Menopause Related Quality of Life Among Health Professionals in University Hospitals of UMC in Nur-Sultan
Completed NCT02274571 - Raising Insulin Sensitivity in Post Menopause Early Phase 1
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT02253173 - Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Recruiting NCT01488903 - A Cohort Research of Genetic Susceptibility for Common Obesity in Women N/A
Terminated NCT01633814 - Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women N/A
Completed NCT00599456 - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women. N/A